EAM Investors’s Arbutus Biopharma ABUS Stock Holding History

EAM Investors’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-342,949	Closed	-$3.24M	–	249
2018 Q3	$3.24M	Buy	+342,949	New	+$3.41M	0.48%	92

Other funds holding ABUS

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EAM Investors's ABUS Position: Q4 2018 in Review

EAM Investors sold out of Arbutus Biopharma (ABUS) in Q4 2018, closing a stake of 342,949 shares — an estimated $3.24M sold.

EAM Investors first reported a position in ABUS in Q3 2018 and held it in 1 quarter. The position peaked at $3.24M in Q3 2018. 71 funds tracked by Wall St. Rank hold ABUS as of Q4 2018.

EAM Investors reported no remaining Arbutus Biopharma position as of Q4 2018 after selling out during the quarter.
EAM Investors sold 342,949 Arbutus Biopharma shares in Q4 2018, an estimated $3.24M.
EAM Investors first reported a position in Arbutus Biopharma in Q3 2018 and held it in 1 quarter.
EAM Investors's Arbutus Biopharma position peaked at $3.24M in Q3 2018.
71 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2018.

Based on EAM Investors's 13F filing for Q4 2018, filed 13 Feb 2019.